OTHER INFORMATION
−Removed: 10.1# Form of Time-Based Restricted Stock Unit Award Agreement under the 2017 IPO Stock Incentive Plan
−Removed: 10.2# Form of Performance-Based Restricted Stock Unit Award Agreement under the 2017 IPO Stock Incentive Plan
+Added: Andrew Orth, the Company’s Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.
+Added: Insider Trading Arrangements
+Added: On June 12, 2023 , Krish Krishnan , our Chief Executive Officer and Chairman of our Board of Directors ,adopted a Rule 10b5 - 1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5 - 1 (c) under the Exchange Act for the sale of up to 100,000 shares of our Common Stock until September 11, 2024.
+Added: On June 12, 2023 , Suma Krishnan , our President, R&D and a member of our Board of Directors , adopted a Rule 10b5 - 1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5 - 1(c) under the Exchange Act for the sale of up to 100,000 shares of our Common Stock until September 11, 2024.
+Added: 10.1 Securities Purchase Agreement, by and among Krystal Biotech, Inc.
+Added: and the institutional investors listed on the signature pages thereto, dated as of May 21, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on May 22, 2023).
+Added: 10.2 Registration Rights Agreement, by and among Krystal Biotech, Inc.
+Added: and the institutional investors listed on the signature pages thereto, dated as of May 21, 2023 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on May 22, 2023).
31.1 Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
3 unchanged sentences
101 Inline XBRL (Extensible Business Reporting Language).
−Removed: The following materials from this Quarterly Report on Form 10-Q for the period ended March 31, 2023, are formatted in Inline XBRL:
+Added: The following materials from this Quarterly Report on Form 10-Q for the period ended June 30, 2023, are formatted in Inline XBRL:
(i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc.
2 unchanged sentences
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL.
−Removed: # Indicates a management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KRYSTAL BIOTECH, INC.
+Added: August 7, 2023
President and Chief Executive Officer
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.